title: Hypofractionated radiotherapy for localized prostate cancer using three-dimensional conformal radiotherapy technique: 3 years toxicity analysis.
abstract: BACKGROUND
  Hypofractionated radiotherapy in the radical treatment of localized prostate cancer has potential biological advantages relative to conventional fractionation. We report prospectively collected toxicity data from a cohort of patients treated with a 3D conformal technique (3DCRT).
  
  
  METHODS
  90 patients receiving curative intent hypofractionated radiotherapy with 57Gy in 19 daily fractions over 3.8 weeks were evaluated prospectively for the development of radiation related toxicity over a 3 year period.
  
  
  RESULTS
  All patients completed treatment. Maximal acute toxicity experienced was 58.6, 10 and 1.1% for grade 1, 2 and 3 genitourinary (GU) toxicity respectively and 75.6, 9 and 0% for gastrointestinal (GI) toxicity. For late toxicity the three year actuarial rates of grade 1, 2 and 3 GU and GI toxicity respectively were 47.3, 2.4 and 0%; and 40, 9.3 and 4.7%. There were no grade 4 or worse acute or late toxicities. 97.6% of evaluable patients remained free of biochemical failure 36 months post radiotherapy.
  
  
  CONCLUSIONS
  A 57Gy in 19 daily fraction radiotherapy schedule using 3D conformal radiotherapy for the definitive treatment of localized prostate cancer has acceptable early and late toxicity.
authors.affiliation: Department of Clinical Oncology, Mount Vernon Cancer Centre, Northwood, United Kingdom.
authors.forename: R
authors.initials: R
authors.lastname: White
authors.forename: D
authors.initials: D
authors.lastname: Woolf
authors.forename: S
authors.initials: S
authors.lastname: Li
authors.forename: R
authors.initials: R
authors.lastname: Alonzi
authors.forename: P
authors.initials: P
authors.lastname: Osler
authors.forename: P
authors.initials: P
authors.lastname: Hoskin
authors.forename: R
authors.initials: R
authors.lastname: Hughes
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019583:Dose Fractionation, Radiation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D020266:Radiotherapy, Conformal / Q000379:methods